Huntersville, NCNCT06999187Now EnrollingIRB Ready

Triple Negative Breast Cancer Clinical Trial in Huntersville, NC

Access cutting-edge triple negative breast cancer treatment through this clinical trial at a research site in Huntersville. Study-provided care at no cost to qualified participants.

Sponsored by Dren Bio

Quick Self-Assessment

See if you qualify for this Huntersville location

Preparing your pre-screening questions…

Expert Care in Huntersville

Access triple negative breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related triple negative breast cancer treatment provided free

Apply for This Huntersville Location

Check if you qualify for this triple negative breast cancer clinical trial in Huntersville, NC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Huntersville

    Convenient for NC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Huntersville site if eligible
  4. 4Begin participation

About This Triple Negative Breast Cancer Study in Huntersville

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

Sponsor: Dren Bio

Who Can Participate

Inclusion Criteria

Histologically confirmed epithelial cancer of the following tumor types: breast (TNBC, HR+/HER2-/+BC), NSCLC, cervical, CRPC, PDAC, HNSCC, endometrial, ovarian, gastric/GEJ, or urothelial that is unresectable, locally advanced or metastatic
Relapsed or refractory with at least 2 prior lines of therapy and for which no standard of care treatment options are available
Radiographically measurable disease
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Life expectancy, in the opinion of the Investigator, of ≥ 3 months
Adequate marrow reserve, renal function, and hepatic function
Taper of ≥ 2 weeks from high-dose systemic corticosteroids (however, low dose corticosteroids ≤ 25 mg prednisone or equivalent daily are permitted in consultation with the Medical Monitor)
Willing to provide archival tumor tissue samples or agree to a baseline biopsy if not available
Willing to undergo an on-treatment biopsy if clinically feasible and not contraindicated at the time of procedure

Exclusion Criteria

Major surgery within 28 days prior to Day 1
Have not had an appropriate washout period from systemic therapy, including investigational agents, prior to C1D1:
Systemic chemotherapy and anticancer therapies within 4 weeks or 5 half-lives of the drug, whichever is shorter.
Antibody-based anticancer therapy: ≥ 4 weeks. Note: Treatment with systemic corticosteroids ≤ 25 mg/day (prednisone or equivalent) and inhaled or topical steroids are allowed. For participants with CRPC, LHRH agents are allowed.
Radiation therapy within 21 days prior to C1D1. Palliative radiation therapy may be allowed following discussion with Medical Monitor
Brain metastases either untreated and symptomatic or requiring therapy with steroids or anticonvulsants to control associated symptoms. Brain metastases that have been treated and are no longer symptomatic are allowed if use of high-dose systemic corticosteroids (\> 25 mg/day of prednisone or equivalent) is stopped ≥ 12 weeks prior to C1D1.
Active Grade ≥ 2 anorexia, nausea or vomiting, and/or signs of intestinal obstruction.
Another malignancy (except for adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated with no evidence of disease for ≥ 1 year)
Evidence of significant, uncontrolled concomitant disease that could affect compliance with study.
Current or past history of CNS disease, such as stroke, epilepsy, central nervous system vasculitis or neurodegenerative disease (participants with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 6 months and have no residual neurologic deficits may be eligible).
QT interval for heart rate using Fridericia's formula (QTcF) \> 480 msec or history of additional risk factors for Torsades de Pointes
Uncontrolled or significant cardiovascular disease
History or presence of an abnormal ECG that is clinically significant in the Investigator's opinion or myocardial infarction within 6 months prior to C1D1.
Prior solid organ transplantation.
Known infection with HIV, HBV, or HCV. The following participants may be enrolled in this study (the Sponsor reserves the right to restrict enrollment of these participants):
Participants who are HIV-positive with undetectable HIV RNA and at least 3 months on antiretroviral therapy.
Participants with a positive serologic test for HBV (i.e., positive HBcAb and negative HBsAg) and have a negative PCR test.
Participants who are HCV-positive who have completed at least 1 month of highly effective antiviral therapy and have a negative PCR test.
Active infection requiring systemic treatment, defined as requiring IV antimicrobial, antifungal, or antiviral agents within 2 weeks prior to C1D1. Prophylactic antimicrobial treatment is allowed. Infections eligible per Exclusion Criterion 16 may be enrolled.
Active clinical interstitial pneumonitis (e.g., shortness of breath, requirement of supplemental oxygen, dry cough) or as confirmed by means of diagnostic imaging within 6 months prior to C1D1.
Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Huntersville?

Yes, this clinical trial (NCT06999187) has an active research site in Huntersville, NC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Triple Negative Breast Cancer Treatment Options in Huntersville, NC

If you're searching for triple negative breast cancer treatment options in Huntersville, NC, this clinical trial (NCT06999187) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Huntersville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced triple negative breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all triple negative breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Huntersville, NC

See all breast cancer clinical trials recruiting in Huntersville — not just this study.

Browse Breast Cancer Trials in Huntersville →

Browse More Trials by Condition

Breast Cancer TrialsTriple Negative Breast Cancer TrialsAnkylosing Spondylitis TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Huntersville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Huntersville, NC